CT-Guided Percutaneous Cryoablation of Breast Cancer: A Single-Center Experience.
Thomas Joseph VoglJohn BielfeldtUlrich KüblerHamzah AdwanPublished in: Cancers (2024)
This study shall retrospectively evaluate the efficacy and safety of liquid-nitrogen based CT-guided cryoablation (CA) as a minimal-invasive technique for the curative treatment of primary breast cancer. A total of 45 female patients with 56 tumors were treated by CT-guided CA in analgosedation as an outpatient procedure. We used a liquid-nitrogen based system with a single cryoprobe and performed two freeze cycles with an intermediate thawing. The mean tumor diameter was 1.6 ± 0.7 cm. Follow-up was conducted via contrast-enhanced MR images of the breast. No complications were observed in all 56 ablations. Initial complete ablation was achieved in 100% of cases. Four cases of local tumor progression were reported, resulting in a rate of 8.9%, and 6 cases of intramammary distant recurrence at a rate of 13.3%. The extramammary tumor progression was observed in 7 patients at a rate of 15.6%. The mean overall survival was 4.13 years (95% CI: 3.7-4.5). The mean overall progression-free survival was 2.5 years (95% CI: 1.8-3.2) and the mean local progression-free survival was 2.9 years (95% CI: 2.3-3.6). Cryoablation is a safe and effective treatment for primary breast cancer tumors, which can be performed in analgosedation and as an outpatient procedure. However, potential for improvement exists and further evidence is necessary.
Keyphrases
- free survival
- contrast enhanced
- magnetic resonance imaging
- diffusion weighted
- computed tomography
- dual energy
- magnetic resonance
- diffusion weighted imaging
- image quality
- poor prognosis
- positron emission tomography
- deep learning
- combination therapy
- lymph node
- ionic liquid
- prognostic factors
- optical coherence tomography
- ultrasound guided
- convolutional neural network
- smoking cessation
- pet ct
- long non coding rna